vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Mistras Group, Inc. (MG). Click either name above to swap in a different company.
Mistras Group, Inc. is the larger business by last-quarter revenue ($181.5M vs $139.2M, roughly 1.3× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 2.1%, a 33.4% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 5.1%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $26.0M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -0.8%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Mistras Group, Inc. is a global provider of asset integrity and protection solutions, offering non-destructive testing, inspection, real-time monitoring, and engineering consulting services. Its key client segments include oil and gas, aerospace, power generation, and manufacturing industries, with operations spanning North America, Europe, and Asia-Pacific, helping clients enhance operational safety, extend asset lifespans, and minimize unplanned downtime.
ADMA vs MG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $181.5M |
| Net Profit | $49.4M | $3.8M |
| Gross Margin | 63.8% | 28.4% |
| Operating Margin | 45.1% | 7.0% |
| Net Margin | 35.5% | 2.1% |
| Revenue YoY | 18.4% | 5.1% |
| Net Profit YoY | -55.9% | -27.4% |
| EPS (diluted) | $0.20 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $181.5M | ||
| Q3 25 | $134.2M | $195.5M | ||
| Q2 25 | $122.0M | $185.4M | ||
| Q1 25 | $114.8M | $161.6M | ||
| Q4 24 | $117.5M | $172.7M | ||
| Q3 24 | $119.8M | $182.7M | ||
| Q2 24 | $107.2M | $189.8M | ||
| Q1 24 | $81.9M | $184.4M |
| Q4 25 | $49.4M | $3.8M | ||
| Q3 25 | $36.4M | $13.1M | ||
| Q2 25 | $34.2M | $3.0M | ||
| Q1 25 | $26.9M | $-3.2M | ||
| Q4 24 | $111.9M | $5.2M | ||
| Q3 24 | $35.9M | $6.4M | ||
| Q2 24 | $32.1M | $6.4M | ||
| Q1 24 | $17.8M | $995.0K |
| Q4 25 | 63.8% | 28.4% | ||
| Q3 25 | 56.3% | 29.8% | ||
| Q2 25 | 55.1% | 29.1% | ||
| Q1 25 | 53.2% | 25.3% | ||
| Q4 24 | 53.9% | 26.5% | ||
| Q3 24 | 49.8% | 26.8% | ||
| Q2 24 | 53.6% | 27.1% | ||
| Q1 24 | 47.8% | 25.0% |
| Q4 25 | 45.1% | 7.0% | ||
| Q3 25 | 38.0% | 10.4% | ||
| Q2 25 | 35.1% | 4.5% | ||
| Q1 25 | 30.4% | -0.6% | ||
| Q4 24 | 32.6% | 6.1% | ||
| Q3 24 | 33.1% | 6.5% | ||
| Q2 24 | 36.6% | 6.3% | ||
| Q1 24 | 26.7% | 3.0% |
| Q4 25 | 35.5% | 2.1% | ||
| Q3 25 | 27.1% | 6.7% | ||
| Q2 25 | 28.1% | 1.6% | ||
| Q1 25 | 23.4% | -2.0% | ||
| Q4 24 | 95.2% | 3.0% | ||
| Q3 24 | 30.0% | 3.5% | ||
| Q2 24 | 29.9% | 3.4% | ||
| Q1 24 | 21.7% | 0.5% |
| Q4 25 | $0.20 | $0.12 | ||
| Q3 25 | $0.15 | $0.41 | ||
| Q2 25 | $0.14 | $0.10 | ||
| Q1 25 | $0.11 | $-0.10 | ||
| Q4 24 | $0.45 | $0.17 | ||
| Q3 24 | $0.15 | $0.20 | ||
| Q2 24 | $0.13 | $0.20 | ||
| Q1 24 | $0.08 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $28.0M |
| Total DebtLower is stronger | $72.1M | $178.0M |
| Stockholders' EquityBook value | $477.3M | $235.1M |
| Total Assets | $624.2M | $578.8M |
| Debt / EquityLower = less leverage | 0.15× | 0.76× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $28.0M | ||
| Q3 25 | $61.4M | $27.8M | ||
| Q2 25 | $90.3M | $20.0M | ||
| Q1 25 | $71.6M | $18.5M | ||
| Q4 24 | $103.1M | $18.3M | ||
| Q3 24 | $86.7M | $20.4M | ||
| Q2 24 | $88.2M | $17.2M | ||
| Q1 24 | $45.3M | $16.9M |
| Q4 25 | $72.1M | $178.0M | ||
| Q3 25 | $72.4M | $202.3M | ||
| Q2 25 | — | $189.4M | ||
| Q1 25 | — | $171.9M | ||
| Q4 24 | $72.3M | $169.6M | ||
| Q3 24 | — | $189.7M | ||
| Q2 24 | — | $199.7M | ||
| Q1 24 | — | $198.4M |
| Q4 25 | $477.3M | $235.1M | ||
| Q3 25 | $431.2M | $227.4M | ||
| Q2 25 | $398.3M | $215.8M | ||
| Q1 25 | $373.4M | $198.7M | ||
| Q4 24 | $349.0M | $198.6M | ||
| Q3 24 | $231.9M | $205.2M | ||
| Q2 24 | $188.3M | $193.2M | ||
| Q1 24 | $153.7M | $187.1M |
| Q4 25 | $624.2M | $578.8M | ||
| Q3 25 | $568.7M | $596.3M | ||
| Q2 25 | $558.4M | $571.0M | ||
| Q1 25 | $510.6M | $526.8M | ||
| Q4 24 | $488.7M | $523.0M | ||
| Q3 24 | $390.6M | $551.7M | ||
| Q2 24 | $376.4M | $548.1M | ||
| Q1 24 | $350.9M | $542.1M |
| Q4 25 | 0.15× | 0.76× | ||
| Q3 25 | 0.17× | 0.89× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | 0.21× | 0.85× | ||
| Q3 24 | — | 0.92× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | — | 1.06× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $32.1M |
| Free Cash FlowOCF − Capex | $34.6M | $26.0M |
| FCF MarginFCF / Revenue | 24.8% | 14.3% |
| Capex IntensityCapex / Revenue | 0.8% | 3.4% |
| Cash ConversionOCF / Net Profit | 0.72× | 8.55× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $8.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $32.1M | ||
| Q3 25 | $13.3M | $4.5M | ||
| Q2 25 | $21.1M | $-9.3M | ||
| Q1 25 | $-19.7M | $5.6M | ||
| Q4 24 | $50.2M | $25.7M | ||
| Q3 24 | $25.0M | $19.4M | ||
| Q2 24 | $45.6M | $4.5M | ||
| Q1 24 | $-2.2M | $604.0K |
| Q4 25 | $34.6M | $26.0M | ||
| Q3 25 | $-1.1M | $-4.1M | ||
| Q2 25 | $18.7M | $-14.7M | ||
| Q1 25 | $-24.4M | $1.1M | ||
| Q4 24 | $47.5M | $22.1M | ||
| Q3 24 | $24.0M | $14.6M | ||
| Q2 24 | $43.6M | $-284.0K | ||
| Q1 24 | $-4.6M | $-4.2M |
| Q4 25 | 24.8% | 14.3% | ||
| Q3 25 | -0.8% | -2.1% | ||
| Q2 25 | 15.3% | -7.9% | ||
| Q1 25 | -21.2% | 0.7% | ||
| Q4 24 | 40.4% | 12.8% | ||
| Q3 24 | 20.0% | 8.0% | ||
| Q2 24 | 40.7% | -0.1% | ||
| Q1 24 | -5.6% | -2.3% |
| Q4 25 | 0.8% | 3.4% | ||
| Q3 25 | 10.7% | 4.4% | ||
| Q2 25 | 2.0% | 2.9% | ||
| Q1 25 | 4.1% | 2.8% | ||
| Q4 24 | 2.3% | 2.1% | ||
| Q3 24 | 0.9% | 2.6% | ||
| Q2 24 | 1.9% | 2.5% | ||
| Q1 24 | 2.9% | 2.6% |
| Q4 25 | 0.72× | 8.55× | ||
| Q3 25 | 0.36× | 0.34× | ||
| Q2 25 | 0.62× | -3.07× | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | 4.96× | ||
| Q3 24 | 0.70× | 3.02× | ||
| Q2 24 | 1.42× | 0.71× | ||
| Q1 24 | -0.12× | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
MG
Segment breakdown not available.
